Pembrolizumab plus irinotecan for advanced melanoma
Part of Cancer, Skin clinical trials.
This trial tests combining two drugs—pembrolizumab (an immunotherapy that helps your immune system fight cancer) and irinotecan (a chemotherapy drug)—for people with advanced melanoma. It aims to see if this combination is safe and effective for those who have not yet been treated for metastatic disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have melanoma (not in the eye) that has spread to other parts of the body or cannot be removed by surgery.
- You must be 19 years or older.
- You should be able to take care of yourself (be up and about, not bedridden).
- You must not have had any prior treatment for metastatic melanoma, or if you had adjuvant immunotherapy (like pembrolizumab), it must have been more than 6 months ago.
- If you have brain metastases, they must be stable and not requiring steroids.
- Your kidney, liver, and blood counts must be within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of daily low-dose cyclophosphamide (a chemotherapy pill) and pembrolizumab (an immunotherapy) in people with advanced melanoma that has stopped responding to prior immunotherapy. The goal is to see if this combination can help shrink tumors or slow the disease.
This study tests how well immunotherapy drugs like pembrolizumab and nivolumab work for people with advanced melanoma that has spread. It aims to find markers that predict treatment response.
This trial tests whether giving immunotherapy before surgery and possibly skipping some after may help people with advanced but removable melanoma. It aims to see if this approach can reduce the chance of the cancer coming back.
This trial tests a combination of three immunotherapy drugs (fianlimab, cemiplimab, and ipilimumab) for people with advanced melanoma that has stopped responding to previous PD-1/PD-L1 treatment. It aims to see if this new combination can help shrink or control the cancer.
This study tests a combination of three drugs (relatlimab, ipilimumab, and nivolumab) as a first treatment for advanced melanoma that cannot be removed by surgery. All participants will receive the drug combination, and the study will look at safety and how well it works.
This trial studies whether adding lifileucel (a patient-specific immune-cell treatment) to pembrolizumab works better than pembrolizumab alone. It’s for people with untreated advanced melanoma that cannot be removed by surgery.
Hear when a new Unresectable or Metastatic Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.